Breast cancer drug shows promise in those resistant to trastuzumab

07/28/2009 | Reuters

A midstage trial showed at least five partial responses in terms of tumor shrinkage to a combination of trastuzumab and Ariad Pharmaceuticals' breast cancer treatment ridaforolimus. The study involved patients with metastatic breast cancer who had developed resistance to trastuzumab.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care